Six-Month Clinical and Angiographic Results of Paclitaxel Eluting Simpax Stent

Abstract

Introduction: We aimed to evaluate the safety and efficacy of the simpax stent in the treatment of different patient groups. Patients and Methods: Forty-five patients were treated with the simpax stent. Of these patients, 23 patients gave consent for six months of follow-up by quantitative coronary angiography (QSA) and six patients were evaluated by exercise electrocardiographic test. Only the patients having lesions with stenosis > 50% of diameter and lengths > 16 mm with reference diameters < 2.75 mm were included. Results: The device success rate was 100% and procedure success rate was 97.7%. The mean stent length was 24.6 ± 7.3 mm and stent size was 2.54 ± 0.24 mm. The overall six months incidence of major adverse cardiac events (MACE) was 8.8%. MACE was consisted of two cases of non-Q wave myocardial infarction and two cases of repeated revascularization of the target lesion. MACE rate was higher in chronic total occlusion (CTO) group than non-CTO group (respectively 33.3% and 5.1). Also when compared to stent size, MACE rate was 25% in < 2.5 mm, 0% ? 2.5 mm. The QSA results at six months showed in-stent late lumen loss witha diameter of 0.25 ± 0.15 mm in 17 patients. Conclusion: The six month results in this study demonsrated excellent procedural and device success. Simpax stent was associated with a low in-stent late lumen loss. Also this study showed simpax stent was a safe and effective device in non-CTO group with stent size ? 2.5 mm.